A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China
Xun-Ya Hou, Donald P McManus, Darren J Gray, Julie Balen, Xin-Song Luo, Yong-Kang He, Magda Ellis, Gail M Williams, Yue-Sheng Li
Volume 86, Number 10, October 2008, 788-795
Table 2. Demographic/clinical data and water exposure of subjects in various treatment groups at baseline
| Characteristics | Group A(n = 53) | Group B(n = 56) | Group C(n = 45) | Group D(n = 51) | P-value |
|---|---|---|---|---|---|
| 24.9 (15.1) | 23.6 (14.0) | 19.4 (10.4) | 20.7 (12.3) | 0.147 | |
| Male/female | 49/4 | 51/5 | 43/2 | 49/2 | 0.674 |
| 48.6 (15.6) | 47.1 (14.8) | 45.0 (15.8) | 43.9 (16.1) | 0.420 | |
| Farmer | 9 (17.0%) | 10 (17.9%) | 1 (2.2%) | 8 (15.7%) | 0.067 |
| Fisherman | 14 (26.4%) | 9 (16.1%) | 3 (6.7%) | 3 (5.9%) | 0.009 |
| Businessman | 6 (11.3%) | 4 (7.1%) | 13 (28.9%) | 8 (15.7%) | 0.123 |
| Student | 24 (45.3%) | 33 (58.9%) | 28 (62.2%) | 32 (62.7%) | 0.630 |
| Mean (SD) | 15.0 (17.9) | 8.7 (15.9) | 12.6 (17.9) | 10.2 (16.4) | 0.097 |
| Median (range) | 2 (1–49) | 1 (1–61) | 3 (1–60) | 1 (1–56) | 0.078 |
| 9 (1–46) | 9 (1–38) | 10 (2–30) | 9 (2–30) | 0.711 | |
| 38.3 (1.0) | 38.5 (0.8) | 38.7 (1.2) | 38.2 (1.1) | 0.108 | |
| Fatigue | 48 (90.6%) | 45 (80.4%) | 44 (97.8%) | 43 (84.3%) | 0.450 |
| Loss of appetite | 33 (66.0%) | 36 (67.9%) | 34 (82.2%) | 33 (68.6%) | 0.288 |
| Cough | 23 (43.4%) | 25 (44.6%) | 28 (62.2%) | 31 (60.8%) | 0.100 |
| Dizziness | 27 (50.9%) | 26 (46.4%) | 28 (62.2%) | 22 (43.1%) | 0.267 |
| Diarrhoea | 19 (35.8%) | 29 (51.8%) | 17 (37.8%) | 17 (33.3%) | 0.199 |
| Abdominal distension | 12 (22.6%) | 16 (28.6%) | 15 (33.3%) | 11 (21.6%) | 0.522 |
| Abdominal pain | 6 (11.3%) | 12 (21.4%) | 9 (20.0%) | 10 (19.6%) | 0.521 |
| Hepatomegaly | 23 (43.4%) | 27 (48.2%) | 17 (37.7%) | 18 (35.3%) | 0.535 |
| Splenomegaly | 6 (11.3%) | 11 (19.6%) | 6 (13.3%) | 5 (9.8%) | 0.459 |
SD, standard deviation.